# Phase 2 Non-alcoholic Fatty Liver Disease trials: 29 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials in phase 2 for Non-alcoholic Fatty Liver Disease that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Non-alcoholic Fatty Liver Disease trials: 29 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/non-alcoholic-fatty-liver-disease

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 29
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933328 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD) | Regeneron Pharmaceuticals | Phase 2 | Not yet recruiting | Alcohol-Associated Liver Disease, ALD | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933328) |
| June 9, 2026 | NCT07637006 | Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver | Hong Kong Baptist University | Phase 2 | Not yet recruiting | Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07637006) |
| June 8, 2026 | NCT07631637 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis, MASH | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631637) |
| April 14, 2026 | NCT07527910 | A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527910) |
| March 19, 2026 | NCT07481734 | Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease | Hudson Biotech | Phase 2 | Recruiting | Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481734) |
| December 30, 2025 | NCT07310407 | Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | Ain Shams University | Phase 2 | Not yet recruiting | NAFLD | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07310407) |
| December 29, 2025 | NCT07308548 | A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH ) | Hinova Pharmaceuticals Inc. | Phase 2 | Recruiting | NAFLD (Non-alcoholic Fatty Liver Disease) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07308548) |
| December 17, 2025 | NCT07288138 | A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and... | Eccogene | Phase 2 | Recruiting | Metabolic Dysfunction-associated Steatohepatitis | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288138) |
| September 26, 2025 | NCT07193927 | Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A... | AB Biotics, SA | Phase 2 | Recruiting | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic, Overweight (BMI... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07193927) |
| April 9, 2025 | NCT06920043 | A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH | GlaxoSmithKline | Phase 2 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06920043) |
| March 7, 2025 | NCT06863376 | Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients | Tanta University | Phase 2 | Recruiting | Non-Alcoholic Fatty Liver Disease | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06863376) |
| October 28, 2024 | NCT06661538 | Implementing Food Referrals for Equity and Sustained Health | University of California, San Diego | Phase 2 | Recruiting | Food Insecurity | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06661538) |
| September 19, 2024 | NCT06599918 | Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Phase 2 | Recruiting | Fatty Liver, Obesity, Hepatic Fibrosis, NAFLD, Nicotinamide, Overweight and Obese Adults | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06599918) |
| September 19, 2024 | NCT06588699 | Digoxin In NASH (CODIN) | Yale University | Phase 2 | Recruiting | NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash, MASH With Fibrosis, MASLD, Fatty Liver... | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06588699) |
| August 26, 2024 | NCT06569524 | Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic... | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Non-alcoholic Steatohepatitis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06569524) |
| June 27, 2024 | NCT06477146 | Milk Thistle Clinical Trial in Pediatric NAFLD | University Hospitals Cleveland Medical Center | Phase 2 | Recruiting | Non-Alcoholic Fatty Liver Disease (NAFLD) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06477146) |
| April 9, 2024 | NCT06355310 | Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease | Sponsor not shown (see the record) | Phase 2 | Recruiting | Non-Alcoholic Fatty Liver Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06355310) |
| December 7, 2023 | NCT06160271 | Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven... | Central Hospital, Nancy, France | Phase 2 | Not yet recruiting | Non-alcoholic Steatohepatitis | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06160271) |
| November 15, 2023 | NCT06133101 | Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD) | Sponsor not shown (see the record) | Phase 2 | Recruiting | Non-Alcoholic Fatty Liver Disease | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06133101) |
| August 9, 2023 | NCT05984745 | Effect of CoQ10 on the Outcome of MAFLD Patients | Ain Shams University | Phase 2 | Recruiting | Fatty Liver, NAFLD | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05984745) |
| May 6, 2023 | NCT05842512 | Study of ADI-PEG 20 Versus Placebo in Subjects With NASH | Polaris Group | Phase 2 | Recruiting | Nonalcoholic Steatohepatitis (NASH) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05842512) |
| April 27, 2023 | NCT05832229 | Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | Recruiting | Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious... | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05832229) |
| September 2, 2022 | NCT05526144 | Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans | VA Office of Research and Development | Phase 2 | Recruiting | Nonalcoholic Steatohepatitis, Liver Fibrosis | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05526144) |
| July 29, 2022 | NCT05480696 | Soluble Fibre Supplementation in NAFLD | McMaster University | Phase 2 | Recruiting | Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Hepatic Steatosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05480696) |
| June 21, 2022 | NCT05424003 | Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant | University of Virginia | Phase 2 | Recruiting | NAFLD | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05424003) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 3 |
| Ain Shams University | 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
| University Hospitals Cleveland Medical Center | 1 |
| University of California, San Diego | 1 |
| [AB Biotics, SA](https://specstream.ai/data/clinical-trials/company/ab-biotics-sa) | 1 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 1 |
| Yale University | 1 |
| Tanta University | 1 |
| Hinova Pharmaceuticals Inc. | 1 |
| McMaster University | 1 |
| Hudson Biotech | 1 |
| Eccogene | 1 |
| Hong Kong Baptist University | 1 |
| Central Hospital, Nancy, France | 1 |
| [Polaris Group](https://specstream.ai/data/clinical-trials/company/polaris-group) | 1 |
| University of Florida | 1 |
| University of Virginia | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| Sinew Pharma Inc. | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical) | 1 |
| VA Office of Research and Development | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 15 |
| Egypt | 3 |
| China | 3 |
| Spain | 2 |
| Puerto Rico | 1 |
| United Kingdom | 1 |
| Canada | 1 |
| Taiwan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Transcription services in the United States](https://specstream.ai/data/businesses/transcription-services/united-states)
- [Medical research institutes in the United States](https://specstream.ai/data/businesses/medical-research-institutes/united-states)
- [Dentistry schools in the United States](https://specstream.ai/data/businesses/dentistry-schools/united-states)
- [Venezuelan restaurants in the United States](https://specstream.ai/data/businesses/venezuelan-restaurants/united-states)
- [Music schools in the United States](https://specstream.ai/data/businesses/music-schools/united-states)
- [Ecuadorian restaurants in the United States](https://specstream.ai/data/businesses/ecuadorian-restaurants/united-states)
